Zanamivir

Catalog No.S3007 Synonyms: GG167

For research use only.

Zanamivir (GG167) is a neuraminidase inhibitor used in the treatment and prophylaxis of influenza caused by influenza A virus and influenza B virus.

Zanamivir Chemical Structure

CAS No. 139110-80-8

Selleck's Zanamivir has been cited by 3 Publications

1 Customer Review

Purity & Quality Control

Choose Selective Neuraminidase Inhibitors

Biological Activity

Description Zanamivir (GG167) is a neuraminidase inhibitor used in the treatment and prophylaxis of influenza caused by influenza A virus and influenza B virus.
Targets
neuraminidase [1]
In vitro

Zanamivir, a novel neuraminidase inhibitor, is effective at decreasing replication of the virus in vitro. [1] Zanamivir results in reduced sensitivity in influenza A/H1N1 variant His274Asn, as well as His274Gly, His274Ser, and His274Gln. [2] Zanamivir blocks influenza neuraminidase and prevents the cleavage of sialic acid residues, thus interfering with progeny virus dispersement within the mucosal secretions and reducing viral infectivity. [3] Zanamivir prevents hemadsorption and fusion of persistently infected cells with uninfected cells. Zanamivir reduces the number (but not the area) of plaques if present only during the adsorption period and reduces plaque area (but not number) if added only after the 90-min adsorption period in plaque assays. Zanamivir also reduces the area of plaques formed by a neuraminidase-deficient variant, confirming that its interference with cell-cell fusion is unrelated to inhibition of neuraminidase activity. Zanamivir has no effect on hemadsorption but does inhibit HA2b-red blood cell fusion, as judged by both lipid mixing and content mixing. [4]

In vivo Zanamivir reduces lung titers of the virus and decreases morbidity and mortality in a model of lethal challenge in mice. [1]

Protocol (from reference)

Solubility (25°C)

In vitro

Water 25 mg/mL
(75.23 mM)
DMSO 2 mg/mL
(6.01 mM)
Ethanol Insoluble

Chemical Information

Molecular Weight 332.31
Formula

C12H20N4O7

CAS No. 139110-80-8
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC(=O)NC1C(C=C(OC1C(C(CO)O)O)C(=O)O)N=C(N)N

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04494412 Not yet recruiting Drug: Zanamivir Influenza Human|Arthralgia GlaxoSmithKline January 3 2022 Phase 2
NCT04597437 Not yet recruiting Drug: Zanamivir|Other: Placebo Dengue Fever George Washington University|Naval Medical Research Center|Hospital Infantil de Niño Jesús de Barranquilla (HINJ)|Universidad Bosque|Allied Research Society October 1 2021 Early Phase 1
NCT02377401 Completed Drug: Zanamivir Influenza Human GlaxoSmithKline April 28 2015 Phase 1
NCT01527110 Completed Drug: Intravenous (IV) zanamivir Influenza Human GlaxoSmithKline January 1 2012 Phase 3
NCT01353768 Completed Other: retrospective chart review Infections Respiratory Tract GlaxoSmithKline July 2011 --

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Zanamivir | Zanamivir ic50 | Zanamivir price | Zanamivir cost | Zanamivir solubility dmso | Zanamivir purchase | Zanamivir manufacturer | Zanamivir research buy | Zanamivir order | Zanamivir mouse | Zanamivir chemical structure | Zanamivir mw | Zanamivir molecular weight | Zanamivir datasheet | Zanamivir supplier | Zanamivir in vitro | Zanamivir cell line | Zanamivir concentration | Zanamivir nmr